Cargando…

GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions

With the emergence of various classes of blood glucose-lowering agents, choosing the appropriate drug for each patient is emphasized in diabetes management. Among incretin-based drugs, glucagon-like peptide 1 (GLP-1) receptor agonists are a promising therapeutic option for patients with diabetic kid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Ji Hee, Park, So Young, Lee, Da Young, Kim, Nan Hee, Seo, Ji A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Nephrology 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995488/ https://www.ncbi.nlm.nih.gov/pubmed/35391537 http://dx.doi.org/10.23876/j.krcp.22.001

Ejemplares similares

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
por: Nevola, Riccardo, et al.
Publicado: (2023)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2022)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
por: Kawanami, Daiji, et al.
Publicado: (2020)

GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
por: Górriz, José Luis, et al.
Publicado: (2020)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
por: Rojano Toimil, Alba, et al.
Publicado: (2021)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chia, Chee W, et al.
Publicado: (2009)

Effects of GLP-1 receptor agonists on neurological complications of diabetes
por: García-Casares, Natalia, et al.
Publicado: (2023)

The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
por: Antza, Christina, et al.
Publicado: (2019)

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
por: Chiarelli, Francesco, et al.
Publicado: (2008)

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
por: Oezer, Kuebra, et al.
Publicado: (2023)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
por: Lee, Jinmi, et al.
Publicado: (2012)

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
por: Winiarska, Agata, et al.
Publicado: (2021)

GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art
por: Granata, Antonio, et al.
Publicado: (2022)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
por: del Olmo-Garcia, María Isabel, et al.
Publicado: (2018)

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
por: Nauck, Michael A., et al.
Publicado: (2020)

GLP-1 Based Combination Therapy for Obesity and Diabetes
por: Lee, Young Hee, et al.
Publicado: (2017)

Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence
por: Schechter, Meir, et al.
Publicado: (2023)

The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists
por: van Baar, Michaël J. B., et al.
Publicado: (2019)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
por: Al-Zamel, Noura, et al.
Publicado: (2019)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients
por: Kukla, Aleksandra, et al.
Publicado: (2020)

A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
por: Prasad-Reddy, Lalita, et al.
Publicado: (2015)

GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
por: Gallwitz, Baptist
Publicado: (2015)

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
por: Boye, Kristina S., et al.
Publicado: (2019)

Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
por: Trujillo, Jennifer
Publicado: (2020)

Treatment of Type 2 Diabetes With GLP-1 Receptor Agonists Among Patients With CKD
por: Østergaard, Jakob A., et al.
Publicado: (2022)

The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
por: von Scholten, Bernt Johan, et al.
Publicado: (2022)

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans
por: Koska, Juraj, et al.
Publicado: (2015)

Cellular Senescence and Senotherapies in the Kidney: Current Evidence and Future Directions
por: Docherty, Marie Helena, et al.
Publicado: (2020)

GLP-1 Receptor Agonist Effects on Normal and Neoplastic Pancreata
por: Goggins, Michael
Publicado: (2012)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff, Lisa M, et al.
Publicado: (2010)

Targeting GLP-1 receptor trafficking to improve agonist efficacy
por: Jones, Ben, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_38d0lhc42ufa6hhhavemiuoii3